MDT and patient perspectives on GLP-1 RA therapy and emerging incretin-based dual agonists in T2D and obesity

2022-03-11

touchMDT for touchENDOCRINOLOGY Listen to key experts from a multidisciplinary team and a patient explore the use of GLP-1 RA therapy to treat T2D and obesity, including observations from a patient’s perspective, and consider the evidence for incretin-based dual agonists in development The multidisciplinary team and patient Endocrinologist (diabetes): Professor Carol Wysham, Spokane, WA Endocrinologist (obesity): Dr Ken Fujioka, San Diego, CA Patient: Ms B...

touchMDT for touchENDOCRINOLOGY

Listen to key experts from a multidisciplinary team and a patient explore the use of GLP-1 RA therapy to treat T2D and obesity, including observations from a patient’s perspective, and consider the evidence for incretin-based dual agonists in development

The multidisciplinary team and patient

Endocrinologist (diabetes): Professor Carol Wysham, Spokane, WA
Endocrinologist (obesity): Dr Ken Fujioka, San Diego, CA
Patient: Ms Brittany Jones, Atlanta, GA

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent medical education grant from Eli Lilly. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchendocrinologyime.org/glycemic-control-weight-loss-in-t2d-obesity-incretin-based-dual-agonists/touchENDOCRINOLOGY

Comments (3)